RecruitingNCT07047573

Multi-omics Detection Techniques for Differentiating Benign and Malignant Pulmonary Nodules

Clinical Application Research on Differentiating Benign and Malignant Pulmonary Nodules Based on Multi-omics Detection Technology

Sponsor

Zhao Jun

Enrollment

150 participants

Start Date

Jun 1, 2025

Study Type

OBSERVATIONAL

Conditions

Lung Cancer (Diagnosis)Pulmonary Nodule Persistent

Summary

Research objective: To explore the clinical application effect of multi-omics detection based on flow cytometry analysis, single-cell data and images combined with clinical features in differentiating the benign and malignant nature of pulmonary nodules and the early diagnosis of lung cancer

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is collecting tissue and blood samples from patients who have a lung nodule and are already scheduled for surgery to have it removed. The goal is to use advanced genetic and molecular testing (multi-omics) to better distinguish cancerous from non-cancerous nodules, potentially leading to better diagnostic tools in the future. **You may be eligible if...** - You have a confirmed lung nodule on CT scan - You are already scheduled for surgical removal - A clear pathology (tissue diagnosis) is available or expected - Your clinical data is complete **You may NOT be eligible if...** - You have refused surgical treatment - You have HIV, hepatitis B, or hepatitis C (infectious disease concerns) - You have a condition requiring urgent cancer treatment - You have a clotting disorder or are on blood thinners - You have severe psychiatric illness - You are unable to communicate or follow up long-term Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer

Research on the in vitro Stimulation of Pbmc by Tumor Antigen Nanoparticles PBMCS were isolated from the peripheral blood of hospitalized patients with pulmonary nodules and incubated with nanoparticles loaded with tumor antigens for a specific period of time to detect cancer-related T cells or cytokines in vitro. The content of this type of T cells or cytokines is positively correlated with tumors. On the contrary, the content of T cells or cytokines in patients with benign pulmonary nodules is negatively correlated with the tumor. Furthermore, the benign and malignant nature of pulmonary nodules in patients is determined through the combination of patient imaging data and clinicopathological data.

Locations(1)

Soochow university

Suzhou, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07047573

Related Trials

Blood Based Risk Evaluation With AI for Targeted Primary Health Care in Early Lung Cancer Detection

NCT075525842 locations

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT071689933 locations

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

NCT0746584812 locations

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

NCT074399911 location

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

NCT074106761 location